Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03126591 |
Title | A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Eli Lilly and Company |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | FRA | DNK | BEL |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | United States | Details | |
Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | United States | Details | |
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg | Leuven | 3000 | Belgium | Details | ||
Herlev and Gentofte Hospital | Herlev | 2730 | Denmark | Details | ||
Gustave Roussy | Villejuif Cedex | 94805 | France | Details |